Immunoglobulin G pegylated - Mitsubishi Tanabe Pharma

Drug Profile

Immunoglobulin G pegylated - Mitsubishi Tanabe Pharma

Alternative Names: GB-0998; Human immunoglobulin G - Mitsubishi Tanabe Pharma; Immunoglobulin intravenous - Mitsubishi Tanabe Pharma; Intravenous immunoglobulin - Mitsubishi Tanabe Pharma; Kenketsu Venoglobulin-IH; Polyethylene glycol treated human normal immunoglobulin; Venoglobulin IH

Latest Information Update: 19 Feb 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Developer Japan Blood Products Organization; Mitsubishi Tanabe Pharma Corporation
  • Class Immunoglobulin isotypes
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myasthenia gravis; Dermatomyositis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Agammaglobulinaemia; Bacterial infections; Bronchitis; Dermatomyositis; Myasthenia gravis; Otitis; Pneumonia; Polymyositis
  • Phase III Guillain-Barre syndrome
  • Discontinued Immunodeficiency disorders; Systemic scleroderma

Most Recent Events

  • 29 Oct 2012 Discontinued - Phase-III for Systemic scleroderma in Japan (IV)
  • 29 Oct 2012 Discontinued - Preregistration for Immunodeficiency disorders in Japan (IV)
  • 26 Sep 2011 Launched for Myasthenia gravis in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top